Form 4: Karyopharm Therapeutics Executive Sells Shares to Cover Tax Obligations

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold shares to cover withholding tax liabilities related to vesting restricted stock units.

Summary

• Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics Inc., sold shares of common stock on February 29, 2024, and March 1, 2024.
• The sales were executed under a pre-arranged automatic sale instruction plan adopted on May 18, 2022.
• On February 29, 2024, 16,311 shares were sold at a weighted average price of $1.17, with individual prices ranging from $1.12 to $1.18.
• On March 1, 2024, 6,155 shares were sold at a price of $1.2.
• The sales were conducted to cover withholding tax liabilities incurred upon the vesting of restricted stock units and performance-based restricted stock units.
• Following these transactions, Poulton directly owns 329,511 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales for tax purposes. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales of shares by company executives are a normal part of corporate activity. It is important to consider the context of the sale, such as the reason for the sale and the amount of stock sold, in relation to the executive's total holdings.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates